title: [Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist].
abstract: Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are >25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.
authors.affiliation: UF 21 303 pharmacologie et toxicologie analytique, analyses des éléments traces, fédération de biochimie, hôpital Edouard Herriot, Lyon. francois.parant@chu-lyon.fr
authors.forename: F
authors.initials: F
authors.lastname: Parant
authors.forename: R
authors.initials: R
authors.lastname: Ducluzeau
authors.forename: G
authors.initials: G
authors.lastname: Lardet
authors.forename: M-C
authors.initials: MC
authors.lastname: Gagnieu
authors.forename: M
authors.initials: M
authors.lastname: Moulsma
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004077:Digoxin / Q000097:blood* / Q000276:immunology*; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014462:Ultrafiltration
chemical_list: D007140:Immunoglobulin Fab Fragments; C050199:digoxin antibodies Fab fragments; D004077:Digoxin